[Special Stock] Pharmaresearch, Increasing Domestic and International Rejuran Demand... "High Growth Expected This Year Too"

Pharmaresearch is on the rise. It is interpreted that the analysis by securities firms, which expects high growth this year following strong performance last year, has had an impact.

As of 9:50 AM on the 11th, Pharmaresearch was trading at 289,000 KRW, up 15,500 KRW (5.67%) compared to the previous trading day.

Pharmaresearch recorded sales of 102.6 billion KRW and an operating profit of 33.6 billion KRW in the fourth quarter of last year. This represents increases of 46.7% and 64.9%, respectively, compared to the same period the previous year. Si-on Kang, a researcher at Korea Investment & Securities, said, "While domestic and international demand for Rejuran remains strong, the cosmetics segment, which was sluggish in the third quarter of last year, has recovered."

In particular, growth is expected to continue this year as well. Researcher Kang stated, "The stable growth of the domestic Rejuran market, accelerated exports of medical devices, and positive experiences with Rejuran are leading to an expansion in cosmetics sales, following a textbook pattern. The strategy and timing for entry into major European countries, a key factor for this year, will be concretized in the second quarter (April to June)."

Researcher Tae-gi Ha from Sangsangin Securities also emphasized, "Exports this year will increase to Indonesia, Japan, and newly entered regions, and full-scale promotion of exports to Europe is expected in the second half of the year. Thanks to the halo effect of the Rejuran brand, cosmetics are also expected to show high growth rates." He added, "High growth is expected again this year, proving the status of the original Rejuran brand."